Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RORγt is a thymus-specific isoform of the nuclear receptor RORγ, encoded by the *RORC* gene. It is a ligand-dependent transcription factor and a member of the nuclear receptor superfamily. RORγt acts as a master regulator for the differentiation of naïve CD4+ T cells into Th17 cells. These Th17 cells are characterized by their production of interleukin-17A (IL-17A), which plays key roles in host defense against extracellular pathogens but also contributes to autoimmune pathology when dysregulated. RORγt is primarily expressed in immune cells—most notably T helper 17 (Th17) cells and innate lymphoid cell type 3 (ILC3s).
Modulates transcription of genes involved in Th17 cell differentiation and IL-17 production. Agonists increase activity, while inverse agonists/antagonists decrease activity, often by disrupting coactivator recruitment.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid-related orphan receptor gamma thymus (RORγt).